Clinical Radiology
Volume 65, Issue 8 , Pages 636-641 , August 2010

Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media

  • O. Rees

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: O. Rees, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham LL13 7TD, UK. Tel.: +44 07880 996843; fax: +44 01978 725143.
    • ,
  • S.K. Agarwal

Received 29 November 2009 ,Revised 11 April 2010 ,Accepted 15 April 2010.

References 

  1. Thomsen HS, Marckmann P, Logager CB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;56:3433–3441
  2. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  3. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  4. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis—why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  5. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148–157
  6. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168–175
  7. Todd DJ, Kagan A, Chibnik LB, et al. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433–3441
  8. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–267
  9. Othersen JB, Maize JC, Woolson RF. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179–3185
  10. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. Radiology. 2009;250:371–377
  11. Agarwal R, Brunelli SM, Williams K. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24:856–863
  12. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin N Am. 2009;47:827–831
  13. European Society of Urogenital Radiology . ESUR guideline: gadolinium based contrast media and nephrogenic systemic fibrosis. Available at: http://www.esur.org/Nephrogenic_Fibrosis.39.0.html[Last accessed date: 14.04.2009]
  14. Thomsen HS. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin N Am. 2009;47:871–875
  15. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol. 2007;80:73–76
  16. Idée J, Port M, Dencausse A. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am. 2009;47:855–869
  17. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. Acta Radiol. 2007;48:593–596
  18. Bryant BJ, Im k, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobentate dimeglumine for MRI. Clin Radiol. 2009;64:706–713
  19. Chrysochou C, Buckley DL, Dark P. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging. 2009;29:887–894
  20. Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium based contrast agents. Pediatr Nephrol. 2008;23:2121–2129

PII: S0009-9260(10)00193-5

doi: 10.1016/j.crad.2010.04.012

Clinical Radiology
Volume 65, Issue 8 , Pages 636-641 , August 2010

Article Tools

* Image Usage & Resolution